Abstract
Objectives:To evaluate the effect of pentoxifylline on the quality of life (QoL) in diabetic foot syndrome (DFS) by using Short Form-36 questionnaire, and in reference to the revised neuropathy disability score (RNDS) and grading of diabetic foot.Methods:This randomized placebo-controlled study was carried in the Department of Pharmacology at University of the Sulaimani through 2018. A total number of 80 T2D patients were recruited from outpatients Department attended the Center of Diabetes and the Shar Teaching Hospital in the University of Sulaimani, Sulaimani-Iraq. Group I (non-DFS, n=40) were subgrouped into Group-IA treated with placebo (n=20), and Group-IB treated with 400 mg pentoxifylline thrice daily for 8 weeks. Group II (DFS, n=40) sub grouped into Group-IIA treated with placebo (n=20), and Group-IIB treated with pentoxifylline. The primary outcome measures including the data of SF-36, RNDS, and grading of diabetic foot.Results:Pentoxifylline therapy significantly reduced the RNDS, improved the clinical evidence of diabetic foot, improved the QoL particularly the domains that related to emotional problems and physical health. Pentoxifylline offered a better effect in DFS compared with non-DFS patientsConclusion:Pentoxifylline treatment improves the quality of life in diabetic foot syndrome and its effect is related to the scoring of revised neuropathy disability and grading of diabetic foot.
Highlights
Type-2 diabetes mellitus (T2D) is a chronic multi-systemic disease with microvascular and/ or macrovascular complications
Short term therapy of 400mg thrice daily of PXF for four weeks improves the quality of the life (QoL) in cancer cachexia patients but it deteriorates the QoL after eight weeks treatment without producing a significant effect on the body weight.[10]
The rationale of this study is to evaluate whether the effect of PXF on the diabetic foot syndrome (DFS) differs from the T2D patients without diabetic foot because DFS patients usually suffer from peripheral artery disease
Summary
Type-2 diabetes mellitus (T2D) is a chronic multi-systemic disease with microvascular and/ or macrovascular complications. QoL.[6] Pentoxifylline (PXF) is a phosphodiesterase enzyme that is related to methylxanthine, improves the peripheral circulation by its rheological and vasodilatory properties.[7,8] It is useful in management of the peripheral artery disease.[9] Short term therapy of 400mg thrice daily of PXF for four weeks improves the quality of the life (QoL) in cancer cachexia patients but it deteriorates the QoL after eight weeks treatment without producing a significant effect on the body weight.[10] The rationale of this study is to evaluate whether the effect of PXF on the DFS differs from the T2D patients without diabetic foot because DFS patients usually suffer from peripheral artery disease. This randomized placebo-controlled study aimed to evaluate the effect of PXF on the QoL of T2D patients and DFS and T2D by using SF-36
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
